Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II)

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II)

Neutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn's disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD are reported.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gut 2019-01, Vol.68 (1), p.40-48
Hauptverfasser: Danese, Silvio, Vermeire, Séverine, Hellstern, Paul, Panaccione, Remo, Rogler, Gerhard, Fraser, Gerald, Kohn, Anna, Desreumaux, Pierre, Leong, Rupert W, Comer, Gail M, Cataldi, Fabio, Banerjee, Anindita, Maguire, Mary K, Li, Cheryl, Rath, Natalie, Beebe, Jean, Schreiber, Stefan
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Neutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn's disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD are reported.
ISSN:0017-5749